Follicular lymphoma stage I – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:15:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Follicular lymphoma stage I – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ This clinical trial is studying treatments for B-cell malignancies that have returned or not responded to previous treatments. The study will test different combinations of medications, including BGB-16673, zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. The purpose is to find safe and effective treatment combinations for patients whose cancer has come back or did not respond to earlier treatments.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

]]>